Edina Cenko/Redcliffe Cardiology and Erik Stroes/amsterdamumc.nl
Sep 13, 2026, 16:51
Edina Cenko: AZURE-HeFH Highlights the LDL-C Treatment Gap in HeFH
Edina Cenko, Past-Chairperson ESC Working Group on Coronary Pathophysiology and Microcirculation at European Society of Cardiology, shared on LinkedIn:
“Presented by Erik Stroes at ESC Congress 2026, baseline cohort data from the Phase 3 AZURE-HeFH trial evaluating the novel oral PCSK9 inhibitor laroprovstat vs placebo.
Lifelong cumulative exposure makes aggressive LDL-C lowering essential in HeFH—yet less than 25% hit guideline targets on conventional oral LLT.
- N is 472 genetically or clinically confirmed HeFH participants
- Approximately 21% with prior ASCVD
- 94% on statins (more than 80% high-intensity) and 73.1% on ezetimibe
- Mean baseline LDL-C: 2.95 mmol/L despite intensive combination background therapy
These findings underline the profound implementation gap in HeFH.
Looking forward to primary 12-week and 52-week safety or efficacy outcomes.”
Other posts featuring Edina Cenko on Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC